NCT01559246

Brief Summary

The purpose of this study is to compare short term (up to 48 hours) traditional cardiac rhythm monitoring using a standard ambulatory Holter monitor versus long term (up to 14 days), continuous ambulatory cardiac rhythm monitoring using a new device cleared by the FDA (Zio® Patch), iRhythm Technologies, Inc., San Francisco CA) in patients with suspected cardiac arrhythmias.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
150

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Apr 2012

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

March 9, 2012

Completed
12 days until next milestone

First Posted

Study publicly available on registry

March 21, 2012

Completed
11 days until next milestone

Study Start

First participant enrolled

April 1, 2012

Completed
7 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 1, 2012

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2012

Completed
Last Updated

April 18, 2019

Status Verified

April 1, 2019

Enrollment Period

7 months

First QC Date

March 9, 2012

Last Update Submit

April 17, 2019

Conditions

Keywords

Cardiac Arrhythmia MonitoringHolter MonitoringContinuous ECG monitoringEvent monitoringObservational

Outcome Measures

Primary Outcomes (1)

  • Arrhythmia detection for Zio® patch and the traditional ambulatory Holter monitor.

    Data will be examined to determine the difference in the number of 6 types of arrhythmias detected at maximum observation times of 14 days and 24 hours respectively. In comparing the difference of the number of arrhythmias for the Zio® Patch and the Holter data, we are expecting a skewed distribution of the differences and will use a paired Wilcoxon Signed Rank Test since the normality assumption is not met for a paired t-test. If the difference is significantly greater than zero, there is evidence that the Zio® Patch is an improvement in this sample.

    Up to 14 days.

Secondary Outcomes (1)

  • Subjects ease in comfort for the Zio® Patch and the traditional ambulatory Holter monitor.

    Up to14 days.

Study Arms (1)

Cardiac Arrhythmia

Subjects 18 years of age or greater that have indications for traditional cardiac(Holter) monitoring.

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patients 18 years of age of greater with suspected arrhythmias.

You may qualify if:

  • Are being seen in the outpatient office for evaluation, treatment, or follow-up of arrhythmias;
  • Have a medical history for which ascertaining whether asymptomatic arrhythmias is occurring could be helpful in their treatment plan;
  • Are capable of giving informed consent; assessed by the investigator or the Study Coordinator;
  • Are 18 years of age or older;
  • Able to comply with long term continuous monitoring ECG device.

You may not qualify if:

  • Have known skin allergies, conditions, or sensitivities (e.g. allergy to adhesives, psoriasis) as the Zio(R)Patch should not be used on patients with known skin allergies, conditions, or sensitivities; or
  • Are receiving pacing therapy (e.g., from a pacemaker); or
  • Are anticipated to receive or require external cardiac defibrillation during the monitoring period; or
  • Are anticipated to be exposed to high frequency surgical equipment during the monitoring period.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Scripps Health

La Jolla, California, 92037, United States

Location

Related Publications (1)

  • Barrett PM, Komatireddy R, Haaser S, Topol S, Sheard J, Encinas J, Fought AJ, Topol EJ. Comparison of 24-hour Holter monitoring with 14-day novel adhesive patch electrocardiographic monitoring. Am J Med. 2014 Jan;127(1):95.e11-7. doi: 10.1016/j.amjmed.2013.10.003. Epub 2013 Oct 15.

MeSH Terms

Conditions

Arrhythmias, Cardiac

Condition Hierarchy (Ancestors)

Heart DiseasesCardiovascular DiseasesPathologic ProcessesPathological Conditions, Signs and Symptoms

Study Officials

  • Eric Topol, MD

    Scripps Translational Science Institute

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
PROSPECTIVE
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

March 9, 2012

First Posted

March 21, 2012

Study Start

April 1, 2012

Primary Completion

November 1, 2012

Study Completion

December 1, 2012

Last Updated

April 18, 2019

Record last verified: 2019-04

Locations